MedWatch

Future of Novo Nordisk, Lundbeck and Ascendis Pharma trials in Ukraine remains unclear

Ukraine is home to many clinical trials being run by big Danish pharmaceutical companies, but it’s too early to tell whether development time lines will be impacted by the war.

People leaving Ukraine as Russia begins invasion | Photo: UMIT BEKTAS/REUTERS / X90076

As Russia continues its attempts to take over Kyiv, pharmaceutical companies take stock of how the war might impact drug development plans.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs